Atossa Therapeutics, Inc. Common Stock ATOS
$2.02
-4.72%
at last close
Market Cap$21.16 million
P/E Ratio—
Div Yield—
Volume75.1K
52-Week Range
$1.70$19.35
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $20.67 (+923.1% upside)
Key Stats
- Today's Range
- $1.98 – $2.12
- 50-Day Range
- $1.82 – $3.12
- 52-Week Range
- $1.70 – $19.35
- Volume
- 75K shs
- Average Volume
- 90K shs
- Market Cap
- $21.16 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 15.54%
- Days to Cover
- 1.00
About Atossa Therapeutics, Inc. Common Stock
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Related Stocks
Compare head-to-head: ATOS vs LLY·ATOS vs JNJ·ATOS vs ABBV·ATOS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.